Session Details

Poster Presentations - Research

Sunday, 23 February 2003 16:30 -17:30

Study of Repression in Normal Students
  • Hamid Kamarzarin, Shiraz University
  • Tahereh Hokam Zadeh
  • Health-Related Quality of Life Improvement in Patients with Bipolar Depression Treated with Olanzapine or Olanzapine/Fluoxetine Combination
  • Katarina Kelin, Eli Lilly Australia Pty Limited
  • Lasting Effects of Grooming Training for the Improvement of Satisfaction with Appearance, Self-Esteem and Personal Relationships in Chronic Schizophrenic Inpatients.
  • Soo Yang, The Catholic University of Korea
  • Depression, Anxiety, Stress, and Health Status of People With Spinal Cord Injuries in Thailand: A Transition from Hospital to Home
  • Pisak Chinchai, School of Occupational Therapy, Curtin University of Te
  • Evaluation of Stressors Intensity in Fathers Comparing to Mothers in Those who Have a Child with Leukemia
  • Mehri Golchin, Faculty of Nursing and Midwifery- Isfahan University of
  • Group Cognitive Behavioral Treatment Decreases Anger, Dysphoric Mood and Alters Cellular Immune Parameters in Early Symptomatic HIV Seropositive Patients
  • Lambros Messinis, University Hospital Patras, Greece
  • Effects of the Recurrent Coronary Prevention Project on Type A Behavior Pattern: A Replication Study in Greece
  • Lambros Messinis, University Hospital Patras & Technological and Educatio
  • Correlation Between Parenting Style and Child Development
  • Nahid Fathizadeh, Nursing and Miwifery Faculty
  • Mozhgan Yazdani, Student of Midwifery
  • Paruresis or Shy Bladder Syndrome: Results from U.S. and Canadian Workshops
  • Steven Soifer, University of Maryland School of Social Work
  • Mental Health and Personality Adjustment Among Optimistic and Pessimistic Students
  • SK Srivastava, Department of Psychology, Gurukul Kangri University, HA
  • Metanalysis of Olanzapine/Fluoxetine Use in Treatment-Resistant Depression
  • Jason Russell, Eli Lilly Australia Pty Limited
  • Long-Term Use of Olanzapine/Fluoxetine Combination for Major Depressive Disorder: A 76-Week Study of Efficacy and Safety
  • Issac Schweitzer, The University of Melbourne and Professional Unit, VIC,
  • Onset of Action of Olanzapine/Fluoxetine Combination for Bipolar Depression
  • Jason Russell, Eli Lilly Australia Pty Limited
  • Asking, Not Assuming: Patients Opinions Regarding Antipsychotic Medication, An Update.
  • Brent McGrath, McGill University Health Centre
  • Paranoid Ideations in College Students -The Prediction of Development-
  • Sachiko Morimoto, University of Tokyo
  • An Understanding of the Life and Death from the Perspective of Patients Living with HIV/AIDS in Taiwan
  • Meei-Horng Yang, Department of Nursing, Tri-Service General Hospital
  • The Role of Alcohol and Drugs in Homicide in England and Wales
  • Harriet Bickley, National Confidential Inquiry into Suicide and Homicide
  • Homicide by People with Mental Illness: A National Clinical Survey
  • Harriet Bickley, National Confidential Inquiry into Suicide & Homicide b
  • Change in Clinical Status and Side Effects of Patients Treated with Either Olanzapine or Risperidone: 6-Month Results from the 3-Year Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Observational Study
  • Ruth O'Halloran, Eli Lilly Australia Pty Limited
  • Baseline Characteristics and Clinical Status of Patients Participating in the 3-year Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Observational Study
  • Amanda J Lowry
  • Comparison of Olanzapine and Quetiapine Antipsychotic Treatments for Schizophrenia: 6 Month Results from the 3-year Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Observational Study
  • Shea Morrison, Eli Lilly Australia Pty, Limited
  • The Japanese Mortality Statistics of Intellectual Disabilities in Institutions
  • Noriaki Takeda, Department of Medical Welfare, Faculty of Medical Welfa
  • Role of Risperidone in Psychotic Depression: an Open 8-Weeks Study
  • Jolanta Rabe - Jablonska, II Department of Psychiatry, Medical University of Lodz
  • The Influence of Climatic Conditions Upon Depressive Sufferings in Health Resort Conditions
  • Tamara Gr Vyetrila, Ministry of Health of Ukraine Psycho-Neurological Clini
  • An Open Randiomised Control Trial with the use of the Spiritually Augmented Cognitive Behavior Therapy in Patients with Depression and Hopelessness
  • Russell D'Souza, Mental Health Research Institute
  • An Open Label Study of Quietapine in the Treatment of Rural Patients with Bipolar Disorder and Amphetamine Abuse
  • Russell D'Souza, Mental Health Research Institute
  • Olanzapine Treatment of Rapid-Cycling Bipolar Disorders: An Open Prospective Study
  • Russell D'Souza, Mental Health Research Institute
  • An Open Randomized Control Study Using a Spiritually Augmented Cognitive Behavior Therapy for Demoralization and Treatment Adherence in Patients with Schizophrenia
  • Russell D'Souza, Mental Health Research Institute
  • Olanzapine and Olanzapine/Fluoxetine Combination in the Treatment of Bipolar Depression
  • Gin Malhi, The University of New South Wales, Sydney Australia; Pr
  • Antipsychotics and Diabetes: An Evidence Based Approach
  • Shea Morrison, Eli Lilly Australia Pty, Limited
  • An Observational Study of Patients with Treatment-Resistant Schizophrenia Switched to Olanzapine
  • Jo Inder, Eli Lilly Australia Pty Limited
  • Olanzapine Improves Apparent Motivational Deficits More Than Haloperidol in Patients with Schizophrenia Regardless of Concomitant Anticholinergic Medication Use
  • Ruth A O'Halloran, Eli Lilly Australia Pty, Limited
  • Olanzapine Versus Lithium in Relapse Prevention in Bipolar Disorder: A Randomized Double-Blind Controlled 12-Month Clinical Trial
  • Jo Inder, Eli Lilly Australia Pty Limited
  • Administering Olanzapine to Acutely Ill Patients: The Efficacy of Intramuscular Olanzapine, Oral Olanzapine Rapid Initial Dose Escalation, and Olanzapine Orally Disintegrating Tablet Across Multiple Psychiatric Disorders
  • Amanda J Lowry
  • Serial Measurement of Sexual Function Using the DGSFi in an Olanzapine Switch Trial
  • Anthony Bonnici, Eli Lilly Australia Pty Limited
  • Canadian Multi-Center Trial Assessing Memory and Executive Function in Patients with Schizophrenia Spectrum Disorders Treated with Olanzapine
  • Anthony Bonnici, Eli Lilly Australia Pty Limited